# A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)

> **NCT00723411** · PHASE3 · TERMINATED · sponsor: **Diamyd Therapeutics AB** · enrollment: 334 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** rhGAD65
- **DRUG:** rhGAD65
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00723411
- **Lead sponsor:** Diamyd Therapeutics AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2011-05
- **Final completion:** 2011-08
- **Target enrollment:** 334 (ACTUAL)
- **Why stopped:** The primary endpoint at 15 months was not met.
- **Last updated:** 2011-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00723411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00723411, "A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00723411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*